Kura Oncology (NASDAQ:KURA) vs. Natera (NASDAQ:NTRA) Head-To-Head Review

Natera (NASDAQ:NTRA) and Kura Oncology (NASDAQ:KURA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Natera and Kura Oncology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	2	2	17	2	2.83
Kura Oncology	1	1	11	0	2.77

Natera presently has a consensus price target of $394.31, indicating a potential upside of 22.10%. Kura Oncology has a consensus price target of $25.88, indicating a potential upside of 248.35%. Given Kura Oncology’s higher possible upside, analysts plainly believe Kura Oncology is more favorable than Natera.

Risk & Volatility

Natera has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Profitability

This table compares Natera and Kura Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Natera	-5.66%	-8.61%	-5.93%
Kura Oncology	-369.26%	-336.24%	-46.03%

Insider and Institutional Ownership

99.9% of Natera shares are owned by institutional investors. 5.0% of Natera shares are owned by company insiders. Comparatively, 7.6% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Natera and Kura Oncology”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31 billion	20.31	-$208.16 million	($1.14)	-283.28
Kura Oncology	$67.48 million	10.12	-$278.67 million	($3.37)	-2.20

Natera has higher revenue and earnings than Kura Oncology. Natera is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Natera beats Kura Oncology on 12 of the 15 factors compared between the two stocks.

About Natera

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

About Kura Oncology

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.